Login to Your Account



Lupus Results Steal the Show

Manic Monday: Idenix HCV Win Could Let HGS Salvage Its Deal

By Randy Osborne


Monday, July 20, 2009
Debate seemed certain to bubble this week over the future of Human Genome Sciences Inc.'s deal with Novartis AG for the lackluster hepatitis C virus candidate Albuferon, in light of news due Monday from HGS and probably from another Novartis HCV partner, Idenix Pharmaceuticals Inc.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription